|
|
|
HLA matching
|
| |
47. (1) An AHR treatment provider shall not provide HLA matching except with the consent in writing of the AHRRA where there is an existing child (in this section referred to as the “relevant child”) who has a life-limiting condition who would be the sibling (or half-brother or half-sister) of any child to be born following such matching where—
|
|
| |
(a) no alternative treatment, on the basis of existing scientific and medical evidence, is available to manage the relevant child’s life-limiting condition,
|
|
| |
(b) the treatment of the relevant child’s life-limiting condition with stem cells from the umbilical cord or bone marrow, or transplantation of regenerative tissue, from the child born following HLA matching has a reasonable chance, on the basis of existing scientific and medical evidence, of improving the relevant child’s life-limiting condition, and
|
|
| |
(c) the treatment referred to in paragraph (b) would not be considered, on the basis of existing scientific and medical evidence, to be detrimental to the welfare of the child to be born following HLA matching.
|
|
| |
(2) In this section, “life-limiting condition”, in relation to HLA matching and the relevant child, means a condition which such child has, for which there is no reasonable hope, on the basis of existing scientific and medical evidence, of a cure (other than the treatment referred to in subsection (1)(b)) and from which the child will die.
|
